Nonmyeloablative Allogeneic Transplant

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Aplastic AnemiaParoxysmal Nocturnal HemoglobinuriaAcute Myelogenous LeukemiaAcute Lymphocytic LeukemiaMyelodysplastic SyndromeChronic Myelogenous LeukemiaChronic Lymphocytic LeukemiaHodgkin's LymphomaNon-Hodgkin's LymphomaMantle Cell LymphomaMultiple MyelomaWaldenstrom MacroglobulinemiaBreast CancerRenal Cell CarcinomaMelanomaSarcomaOvarian CancerThymoma
Interventions
PROCEDURE

Nonmyeloablative Allogeneic Transplant

Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day

PROCEDURE

Nonmyeloablative Allogeneic Transplant

Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)

Trial Locations (1)

92037

Scripps Green Hospital, La Jolla

All Listed Sponsors
lead

Scripps Health

OTHER

NCT01272817 - Nonmyeloablative Allogeneic Transplant | Biotech Hunter | Biotech Hunter